Results 271 to 280 of about 97,573 (376)

Tracking immune dysregulation in COVID-19: lymphocyte dynamics from hospitalization to recovery. [PDF]

Braz J Med Biol Res
Eburneo GS, Sousa MB, Brunialti MKC, Santos SS, Silva JGD, Ferreira PRA, Bellei NCJ, Arakaki JSO, Leite GGF, Salomao R.   +9 more
europepmc   +1 more source

Utility of Cytochemical and Flow Cytometry Detection of Alkaline Phosphatase for Differential Diagnosis of CD34+ Acute Leukaemia in Canines

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Alkaline phosphatase (ALP) enzymatic activity has been proposed as a marker for distinguishing canine acute leukaemia (AL) subtypes (i.e., myeloid vs. lymphoid). However, ALP enzymatic activity has not been fully evaluated in CD34+ AL. Determine whether ALP enzymatic activity can differentiate CD34+ AL subtypes in dogs and distinguish CD34+ AL
Megan Aalto, Janna Yoshimoto, Jillian Nolan, Kenzie Olsen, Dylan Ammons, Emily Rout, Anne C. Avery, R. Adam Harris   +7 more
wiley   +1 more source

Dissecting immunophenotypic diversity in multiple myeloma via mass cytometry: a call for harmonized gating strategies. [PDF]

Front Immunol
Singer M, Moloudizargari M, Sanchez J, Pichiorri F.   +3 more
europepmc   +1 more source

Phase 1 Dose Escalation of Single‐Agent Mechlorethamine in Dogs With Lymphoma

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Mechlorethamine is commonly prescribed to dogs at 3 mg/m2. The minimal toxicity observed indicates that higher doses of mechlorethamine are likely tolerable. The primary objective of this study was to determine the maximally tolerated dose (MTD) of mechlorethamine in dogs with lymphoma.
Laura E. Chadsey, Paul R. Hess, Joanne L. Intile   +2 more
wiley   +1 more source

Case Report: A simple case of drug-induced secondary antibody deficiency or a rare primary immune deficiency? [PDF]

Front Immunol
Johnston SL, Evans JC, Berry IR, Watkinson OT.   +3 more
europepmc   +1 more source

Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma – knowledge obtained from the CheckRad-CD8 trial

Markus Hecht, Benjamin Frey, Udo S. Gaipl, Xie Tianyu, Markus Eckstein, Anna-Jasmina Donaubauer, Günther Klautke, Thomas Illmer, Maximilian Fleischmann, Simon Laban, Matthias Hautmann, Bálint Tamaskovics, Thomas Brunner, Ina Becker, Jian‐Guo Zhou, Arndt Hartmann, Rainer Fietkau, Heinrich Iro, Michael Döllinger, Antoniu‐Oreste Gostian, Andreas M. Kist   +20 more
openalex   +1 more source

EXTH-40. IMMUNOPHENOTYPING OF RWTC-MBTA AUTOLOGOUS CANCER VACCINE IN PRECLINICAL GLIOBLASTOMA MODELS [PDF]

Herui Wang, Juan Ye, Rogelio Medina, Yaping Zhang, Samik Chakraborty, Ondřej Uher, Katerina Hadrava Vanova, Jan Ženka, Karel Pacák, Zhengping Zhuang   +9 more
openalex   +1 more source

Diagnostic Evaluation of the Sysmex XN‐1000V Lymphocyte Fluorescence for Differentiating Canine Nodal Large B‐Cell and T‐Cell Lymphoma

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Canine lymphoma is a common haematopoietic neoplasm. Immunophenotype is a major prognostic factor and may influence treatment recommendations. This study assessed the diagnostic performance of the Sysmex XN‐1000V white blood cell differential (WDF) scattergram to differentiate canine nodal large B‐cell and T‐cell lymphoma, using the percentage
Javier Martínez‐Caro, Marta Lemos, Beatriz Agulla, Ignacio Amarillo‐Gómez, Josep Pastor   +4 more
wiley   +1 more source

Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer. [PDF]

Invest New Drugs
Owen DH, Wu R, Wei L, Dikov M, Suman S, Su PL, Amann J, Guan S, Spakowicz D, Schweitzer C, Pilcher C, Smith MB, Ferguson S, Palomino JC, Pérez SF, Bertino EM, Shields PG, He K, Presley CJ, Otterson GA, Carson WE, Carbone DP.   +21 more
europepmc   +1 more source